普瑞巴林治疗焦虑综合症疗效与安全性的系统评价

发布时间：2019-03-18 20:55

【摘要】：【目的】系统评价普瑞巴林治疗焦虑综合症的临床疗效和安全性。【方法】用Cochrane系统评价方法，电子检索CENTRAL、Pubmed、EMbase、中国生物文献数据库文献,评价纳入文献的方法学质量后，采用RevMan5.1.4软件对提取的数据进行分析。【结果】纳入12个随机对照试验，共3471人。对比安慰剂，普瑞巴林治疗广泛性焦虑障碍有效率差异有统计学意义（P＜0.00001，RR=1.34，95%CI=1.20～1.50）；普瑞巴林预防广泛性焦虑障碍复发，复发时间差异有统计学意义（P＜0.0001，HR=0.4，95%CI=0.26～0.61）；普瑞巴林促进广泛性焦虑障碍患者洗脱苯二氮卓类药物，汉密尔顿焦虑量表（HamiltonAnxiety Rating Scale，HAM-A)治疗前后总分改善差异有统计学意义（P＜0.00001，MD=-4.80，95%CI=-5.28～-4.32）；普瑞巴林治疗社交焦虑症有效率差异有统计学意义（P=0.02，RR=1.51，95%CI=1.07～2.13）；普瑞巴林预防社交焦虑症复发，复发时间差异有统计学意义（P=0.04，HR=0.49，95%CI=0.25～0.95）；因不良反应提前退出试验的人数差异无统计学意义（短期试验：P=0.07，RR=1.37，95%CI=0.98～1.91；长期试验：P=0.90，RR=1.12，95%CI=0.21～5.98）。【结论】普瑞巴林治疗广泛性焦虑障碍有效并且安全性好。普瑞巴林在治疗社交焦虑症，维持治疗预防广泛性焦虑障碍和社交焦虑症的复发、促进广泛性焦虑障碍患者洗脱苯二氮卓类药物中显示了一定疗效，但试验数少，总样本量低，，脱落率高，尚不能对普瑞巴林治疗以上疾病的疗效做出明确的结论，确切的疗效有待于更多的设计严格的大样本的随机对照试验加以进一步证实。
[Abstract]:[objective] to evaluate the clinical efficacy and safety of prednisone in the treatment of anxiety syndrome. [methods] the Cochrane system evaluation method was used to search the Chinese biological literature database of CENTRAL,Pubmed,EMbase, electronically. After evaluating the methodological quality of the included literature, the extracted data were analyzed by RevMan5.1.4 software. [results] 3471 people were enrolled in 12 randomized controlled trials. Compared with placebo, there was a significant difference in the effective rate of prazapril in the treatment of generalized anxiety disorder (P < 0.0001, RR = 1.34, 95% CI = 1.20 / 1.50). There was a significant difference in the recurrence time (P < 0.0001, HR = 0.4, 95% CI = 0.26 / 0.61) between the two groups (P < 0.001, HR = 0.4,95% CI = 0.26 / 0.61). There was significant difference in total score improvement before and after treatment (P < 0.00001, P < 0.05, P < 0.01). MD=-4.80,95%CI=-5.28~-4.32); There was a significant difference in the effective rate of prednisone in the treatment of social anxiety disorder (P = 0.02, RR = 1.51, 95% CI = 1.07 / 2.13). There was a significant difference in the recurrence time of prednisone in the prevention of social anxiety disorder (P = 0.04, HR = 0.49, CI = 0.25 / 0.95, P = 0.04, HR = 0.49, P < 0.01). There was no significant difference in the number of people who withdrew from the trial early due to adverse reactions (short-term trials: P0.07, RR / 1.37, 95% CI 0.98 / 1.91; long-term trial: P = 0.90, RR / 1.12, 95% CI = 0.21 / 5.98). [conclusion] Prisbanin is effective and safe in the treatment of generalized anxiety disorder. In the treatment of social anxiety disorder, maintaining treatment to prevent the recurrence of generalized anxiety disorder and social anxiety disorder, and promoting the elution of benzodiazepines in patients with generalized anxiety disorder, ProBahrain has shown a certain curative effect, but the number of trials is small and the total sample size is low. The high drop rate has not yet been able to draw a clear conclusion on the efficacy of prednisine in the treatment of the above diseases, and the exact efficacy needs to be further confirmed in more strictly designed, large sample randomized controlled trials (RCTs).
【学位授予单位】：广西医科大学
【学位级别】：硕士
【学位授予年份】：2012
【分类号】：R749.7

【相似文献】